Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $53.92, for a total value of $21,568.00. Following the completion of the transaction, the vice president now owns 55,588 shares in the company, valued at $2,997,304.96. The trade was a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock traded down $1.11 during trading hours on Monday, hitting $53.93. The company had a trading volume of 478,176 shares, compared to its average volume of 201,225. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -98.05 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81. The firm’s fifty day moving average is $56.58 and its 200 day moving average is $59.03.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. During the same period in the prior year, the company posted $1.05 earnings per share. The business’s revenue for the quarter was up 12.5% compared to the same quarter last year. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ANIP. JPMorgan Chase & Co. increased its holdings in shares of ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after buying an additional 340,854 shares in the last quarter. Global Alpha Capital Management Ltd. increased its holdings in ANI Pharmaceuticals by 1.8% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at $228,000. Thompson Siegel & Walmsley LLC boosted its stake in ANI Pharmaceuticals by 17.6% in the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock worth $13,731,000 after purchasing an additional 34,416 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on ANIP shares. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Raymond James upped their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.